首页 | 本学科首页   官方微博 | 高级检索  
     检索      

基于PK/PD模型对恩诺沙星可溶性粉在鸡混饮给药方案的药效再评价
引用本文:高嫣珺,王美红,聂雅,王震,卜仕金.基于PK/PD模型对恩诺沙星可溶性粉在鸡混饮给药方案的药效再评价[J].畜牧兽医学报,2022,53(9):3199-3207.
作者姓名:高嫣珺  王美红  聂雅  王震  卜仕金
作者单位:扬州大学兽医学院, 江苏省动物重要疫病与人兽共患病防控协同创新中心, 扬州 225009
基金项目:国家肉鸡产业技术体系项目(CARS-42-G23);江苏高校优势学科建设工程资助项目(PAPD)
摘    要:旨在对不同日龄雏鸡开展恩诺沙星可溶性粉混饮给药的药动学研究,并利用获得的药动学参数通过PK/PD模型结合Monte Carlo模拟(Monte Carlo simulation,MCS)评价恩诺沙星可溶性粉推荐给药方案的合理性。分别在1、7和14日龄雏鸡进行恩诺沙星可溶性粉75 mg·L-1(以恩诺沙星计)混饮给药,按预定时间点采集血样,采用经验证的HPLC法测定各时间点每只鸡的血药浓度,拟合药动学参数。将获得的药动学参数与美国临床和实验室标准协会(CLSI)给出的恩诺沙星对禽大肠杆菌的敏感性折点值(0.25 μg·mL-1)结合计算PK/PD参数,并通过MCS获得当前给药方案在大肠杆菌不同MIC分布下的达标率(target attainment rate,TAR)。结果显示,1、7和14日龄雏鸡3个处理组在第0天达峰浓度(Cmax)分别为0.561、0.564和0.550 μg·mL-1,24 h曲线下面积(AUC0-24)分别为8.85、9.85和9.27 μg·h·mL-1;3个处理组给药第4天Cmax分别为0.599、0.550和0.487 μg·mL-1,平均稳态血药浓度(Cavg)分别为0.513、0.493和0.432 μg·mL-1,AUC0-24分别为12.31、11.82和10.37 μg·h·mL-1Cmax/MIC分别为2.40、2.20和1.95,Cavg/MIC分别为2.05、1.97和1.73,AUC0-24/MIC分别为49.24、47.28和41.48。恩诺沙星对MIC≤0.25 μg·mL-1的大肠杆菌临床分离株,1、7和14日龄雏鸡给药期间TAR为75.01%~76.11%。以上结果表明,恩诺沙星可溶性粉按目前的推荐给药方案对敏感菌PK/PD参数比值和TAR均达不到预期,不仅杀菌效果有限,且易诱导细菌产生耐药性。

关 键 词:恩诺沙星  PK/PD模型  Monte  Carlo模拟  雏鸡  
收稿时间:2021-12-13

Reevaluation of the Efficacy of Enrofloxacin Soluble Powder Mixed Drink Administration Regimen in Chicken by Modelling of Pharmacokinetic and Pharmacodynamic Data
GAO Yanjun,WANG Meihong,NIE Ya,WANG Zhen,BU Shijin.Reevaluation of the Efficacy of Enrofloxacin Soluble Powder Mixed Drink Administration Regimen in Chicken by Modelling of Pharmacokinetic and Pharmacodynamic Data[J].Acta Veterinaria et Zootechnica Sinica,2022,53(9):3199-3207.
Authors:GAO Yanjun  WANG Meihong  NIE Ya  WANG Zhen  BU Shijin
Institution:Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China
Abstract:The pharmacokinetics of enrofloxacin soluble powder in the drinking water were investigated in chicks of various ages and the PK/PD model combined with Monte Carlo simulation (MCS) was used to evaluate the rationality of enrofloxacin soluble powder administration by the recommended regimen. Chicks were given 75 mg·L-1 of enrofloxacin soluble powder (calculated by enrofloxacin) at 1, 7 and 14 days of age. At predefined time intervals, blood samples were obtained, the plasma concentration of enrofloxacin was measured by HPLC, and pharmacokinetic parameters were calculated. PK/PD parameters were calculated by combining the pharmacokinetic parameters with the breakpoint (0.25 μg·mL-1) of enrofloxacin against Escherichia coli in poultry obtained by Clinical and Laboratory Standards Institute (CLSI), and the target attainment rate (TAR) of the current administration regimen under different MIC ranges of Escherichia coli was obtained by MCS. The results showed that Cmax of chicks at 1, 7 and 14 days of age were 0.561, 0.564 and 0.550 μg·mL-1 on day 0 of administration, and AUC0-24 were 8.85, 9.85 and 9.27 μg·h·mL-1, respectively. Cmax of chicks at 1, 7, and 14 days of age on day 4 of administration were 0.599, 0.550 and 0.487 μg·mL-1, Cavg were 0.513, 0.493 and 0.432 μg·mL-1; AUC0-24were 12.31, 11.82and 10.37 μg·h·mL-1; Cmax/MIC were 2.40, 2.20 and 1.95; Cavg/MIC were 2.05, 1.97 and 1.73; AUC0-24/MIC were 49.24, 47.28 and 41.48, respectively. When the MIC of enrofloxacin against clinical isolates of Escherichia coli within 0.25 μg·mL-1, TAR varied from 75.01 percent to 76.11 percent at 1, 7, and 14 days of age. The results revealed that enrofloxacin soluble powder failed to achieve the PK/PD parameter ratio and TAR of sensitive bacteria as expected by the currently suggested regimen, which not only limited bactericidal effect, but also easy to induce bacterial drug resistance.
Keywords:enrofloxacin  PK/PD model  Monte Carlo simulation  chick  
点击此处可从《畜牧兽医学报》浏览原始摘要信息
点击此处可从《畜牧兽医学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号